Summary The CYFRA 21-1 assay is a test that has been developed recently for detection of a cytokeratin 19 fragment in serum. A diagnostic role for CYFRA 21-1 has already been proposed. The question of whether this marker is prognostically significant is important in clarifying the role of CYFRA 21-1 in clinical practice. The aim of this study was to evaluate the prognostic significance of elevated preoperative CYFRA 21-1 levels in patients with resected primary squamous-cell lung cancer (SqCC). Serum levels of CYFRA 21-1 were measured using an immunoradiometric assay (CIS bio) in 91 patients with operable SqCC. Survival and disease-free survival curves related to initial levels of this marker were estimated using the Kaplan-Meier method. In the univariate analysis the log-rank test and the log-rank test for trend were used. In the multivariate analysis the stratified log-rank test and the proportional hazard model were used. Elevated preoperative CYFRA 21-1 levels were identified in 55% of patients with SqCC. The number of patients with elevated levels of this marker increased with TNM stage (P=0.0001). In univariate analysis elevated levels of CYFRA 21-1 were significantly associated with poor overall survival (P<0.00005) and with disease-free survival (P<0.00005). In multivariate analysis elevated levels of this marker were also found to be associated with poor overall and disease-free survival (P=0.01 and P=0.003 respectively). In conclusion, CYFRA 21-1 may be an independent prognostic parameter of survival and tumour relapse in SqCC and may be useful in identifying resected SqCC patients at high risk of treatment failure.
Squamous-cell lung carcinoma comprises 40-50% of all cases of lung cancer. Its treatment is primarily surgical and its prognosis has remained almost unchanged over recent years. As is the case with other neoplasma, it would appear valuable to segregate patients with squamous cell lung carcinoma into different prognostic categories at the time of diagnosis because this approach may assist in the selection of types of treatment. Today, for patients with lung carcinoma, the TNM staging system is the most important prognostic factor. However, the variability of survival within staging groups required additional types of indicators, independent of stage to generate a 'comprehensive' estimate of prognosis (Fielding et al., 1992) .
Recently, great attention has been focused on the biology of lung cancer and a number of so-called tumour markers have been described (Richardson and Johnson, 1993; Buccheri and Ferigno, 1994; Mountain, 1995; . One group of molecules that has been shown to be promising as tumour markers is the cytokeratins (Moll et al., 1982) .
Cytokeratins are one of the main families of intermediate filaments which make up the cytoskeleton. A cytokeratin is a heterotypic tetramer of protofilaments composed of two polypeptides: one acidic type I subunit and one basic type II subunit (Nagle, 1988) . It is noteworthy that each type of epithelia and its malignant counterpart expresses a specific cytokeratin pattern. Immunohistochemical studies have demonstrated that simple epithelia, including respiratory epithelia, express cytokeratins 7, 8, 18 and 19 (Moll et al., 1990 Bodenmuler et al., 1994) .
The results of initial studies of CYFRA 21-1 in lung cancer patients showed its dominant value in squamous-cell carcinoma type (Pujol et al., 1993; Stieber et al., 1993; Bombardieri et al., 1994; Rastel et al., 1994; Rapellino et al., 1995) . The current study examines whether elevated serum CYFRA 21-1 levels have any prognostic value in patients with resected squamous-cell lung cancer.
Material and methods
The study includes 91 squamous-cell lung cancer (SqCC) patients examined by the Chest Oncology Group and operated on in the Thoracic Surgery Unit at the Bialystok Medical School between May 1991 and June 1993. All of these patients underwent surgical resection. No patient underwent chemotherapy or radiation therapy before surgery.
Pretreatment staging procedures included physical and blood examinations, chest radiographs and tomographs, bronchoscopy, computed tomography (CT) of the thorax and ultrasound scanning of liver. In addition, radioisotopic scans of bones, examination of bone marrow aspirates and abdominal and brain CT scans were performed when necessary. Selected patients underwent mediastinoscopy. All patients were of good performance status at the time of surgery (Karnofsky, 80 to 100). During operation, radical lymph node dissection was uniformly performed. Nodes were identified and submitted separately at all levels. Pathological material has been specially reviewed for this study by the same pathologist. Post-operative, pathological staging (pTNM) (primary tumour, regional lymph involvement, occurrence of distant metastasis) was performed by correlating the operative and histological findings (Mountain, 1986) . After surgery, patients were followed at 3 month intervals with a clinical and radiological examination.
At the time of our analysis, 30 patients had died. Two patients (2%) died of complications after surgery (operative death) and three patients died 33, 34 and 36 months after surgery, respectively, due to an unrelated cause. In these three cases, no tumour recurrence had been detected. A total of 25 remaining patients had died owing to recurrence of the disease. Three patients with recurrence are alive at 3 months after the second treatment (one patient was able to undergo a second resection, the other two were treated with radiation therapy).
In the whole group of patients (excluding the two patients who died of complications after surgery) the length of followup ranged from 11 to 38 months. In the group of 62 surviving patients, follow-up ranged from 11 to 36 months; 35 of those patients (57.4%) were observed for 36 months after surgery.
To determinate CYFRA 21-1 serum levels, venous blood samples were collected from each patient before surgery, centrifuged to obtain serum samples and stored at -80°C until assayed. All samples were assayed in duplicate. Serum levels of CYFRA 21-1 were measured with immunoradiometric assay, using a commercial source (CIS bio international, Gif/Yvette, France), following the manufacturer's instructions. The cut-off point was 3.6 ng ml-'.
Statistical analysis
Comparisons based on contingency tables were performed using the Fisher's exact test and the exact test for trend (Agresti, 1990) . Survival time was calculated from the time of surgery to the date of death or the last observation of a patient. Patients alive at the end of the follow-up were regarded as censored observations. Disease-free survival time was calculated from the date of surgery to the date of the first occurrence of relapse or death or to the date of the last observation of a patient. Patients alive and free of disease at the end of the follow-up were regarded as censored observations.
Overall survival and disease-free survival curves related to initial serum CYFRA 21-1 level were estimated using the Kaplan-Meier method. Confidence intervals (95%) for the estimated probability of overall and disease-free survival were calculated using the asymptotic variance of the log-log transformation of the survivor function (Kalbfleisch and Prentice, 1980) .
In the univariate analysis of the log-rank test (exact and asymptotic version) and the log-rank test for trend (asymptotic version; Tarone and Ware, 1977) were used. In the multivariate analysis the (exact) stratified log-rank test and proportional hazard model were used. Comparisons CYFRA 21-1 in squamous cell lung cancer J Niklinski et a! % 957 based on multivariate models were performed using the score test. The fit of models was checked both graphically and using time-dependent covariates (Kalbfleisch and Prentice, 1980) .
All the tests performed in the univariate and the multivariate analyses were two-sided. The exact tests were computed using StatXact-Turbo v.2.0 software. Confidence intervals for the estimated probability of overall and diseasefree survival were calculated using Stata v.3.0. The other methods were applied using BMDP/dynamic v.7.0 (programs 11 and 21).
Results
At the time of diagnosis 55% (50/91) of SqCC patients had CYFRA 21-1 levels higher than 3.6 ng ml-'. Concentration of serum CYFRA 21-1 according to patients' characteristics is shown in Table I Overall survival analysis In the analysis 91 patients were included. In this group of patients 30 deaths were observed. Four factors were investigated for their influence on the survival of the patients: sex, age (<50, 50-64, 65 years), TNM stage (I, II, lIla) and the level of CYFRA 21-1 (normal, < 3.6; elevated, > 3.6 ng ml-').
The univariate analysis was based on the results of the logrank test. Taking into account the fact that multiple comparisons were made, the 0.01 level of significance was adopted. The results of the test for age (P<0.00005), TNM (P=0.005) and CYFRA 21.1 level (P<0.00005) were found to be significant (Table II) . The presence of an elevated level of CYFRA 21-1 was associated with a shorter survival time of patients (Figure 1) .
In the multivariate analysis the (exact) stratified log-rank test for the level of CYFRA 21-1 factor, with strata defined by different combinations of age and TNM stage, was used first. The result (P=0.02) was significant at the 0.05 level (Table II) . Secondly, an analysis using the proportional hazard model was performed. It was found that a stratified model (Table III) , with two strata defined by TNM stage (I In the univariate analysis (Table IV) the results of the logrank tests for age (P< 0.00005), TNM (P = 0.003) and CYFRA 21-1 level (P<0.00005) were significant at the 0.01 significance level (adjusted for the multiple comparisons). The presence of an elevated level of CYFRA 21-1 was associated with a shorter disease-free survival time (Figure 2) . The approach to the multivariate analysis was similar to the one chosen in the overall survival case. In the first step, the (exact) stratified log-rank test for CYFRA 21-1 level, with strata defined by different combinations of the age and TNM, was performed. It resulted in P = 0.003, which was significant at the 0.05 significance level.
In an attempt to use the proportional hazard model it was
found that there was a need to use a model stratified by age. However, fitting a model stratified by age with CYFRA 21-1 level as a covariate was impossible because the likelihood function appeared to be monotone in the coefficient related to the covariate (Bryson and Johnson, 1981) . This was due to the fact that among younger patients ( < 64 years) recurrences and deaths without recurrence were observed only for those having elevated levels of CYFRA 21-1, while among the oldest patients (>64 years) there were no recurrences and only one death was observed (for a patient with normal CYFRA 21-1 level). Since it was impossible to fit a model stratified by age, which would contain CYFRA 21-1 as a covariate, it was decided to limit the multivariate analysis of the disease-free survival to the use of the stratified log-rank test.
Discussion
The conventional approach to assessing prognosis in patients with lung cancer has been to place great importance Recently we reported the significant role of CYFRA 21-1 in post-operative monitoring of patients for the detection of iski and Furman, 1995). Additionally it has been tumour recurrence jCC and elevated levels of this marker were correlated disease monitoring with WHO response criteria with therapy progression of tumour stage. In our previous study, we assessed using standard techniques (Gaast et al., 1994) . It was found a significant relationship between the elevated found that 84% of response evaluations yielded concordant of CYFRA 21-1 and mediastinal lymph node results. More data, however, are needed to make sure iement (Niklinski et al., 1994) .
whether the course of CYFRA 21-1 concentrations during Ice the diagnostic role of CYFRA 21-1 has already been therapy reflects precisely the disease status. The present study ited (Stieber et al., 1993; Ebert et al., 1995; Paone et al., suggests that the determination of CYFRA 21-1 may provide Wieskopf et al., 1995) , it is worthwhile investigating additional, independent, prognostic information in squaer pretreatment CYFRA 21-1 concentrations are mous-cell lung cancer patients. related to the likelihood of relapse in lung cancer patients who undergo curative resection.
In this paper we report results aimed at the evaluation of 
